Since the introduction of durable left ventricular assist devices for advanced heart failure, management of antithrombotic ...
Abstract: Left ventricular assist devices (LVADs) have long been used to treat adults with heart failure, but LVAD options for pediatric patients with heart failure are lacking. Despite the urgent ...
Abstract: We have developed a hydrodynamic levitation centrifugal blood pump with a semi-open impeller for a mechanically circulatory assist. The impeller levitated with original hydrodynamic bearings ...
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the ...
Introduction: The HeartMate 3 (HM3) LVAD, was shown to have a higher survival free of hemocompatibility related adverse events (HRAE) compared to its predecessors (HM2, HVAD). Superior HM3 outcomes ...
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...
Avoidance of aspirin as part of an antithrombotic regimen that includes vitamin K antagonists (VKAs) in patients with advanced heart failure (HF) treated and with fully magnetically levitated left ...
Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure
About The Study: This randomized clinical trial found that in patients with advanced heart failure treated with a fully magnetically levitated left ventricular assist device, avoidance of aspirin as ...
These findings resulted in Food and Drug Administration (FDA) approval of the HeartMate 3 for destination therapy in 2018, conditional on an extended evaluation to 5 years of follow-up. The composite ...
Predictors of Longitudinal Change in Cardiac Index during Intra-Aortic Balloon Pump (IABP) Support Receive the the latest news, research, and presentations from major meetings right to your inbox.
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results